IR-XR post48a IR-IR post48b XR-XR post48c Total
Number of patients, n (%) 130 (100) 13 (100) 276 (100) 419 (100)
Baseline HIV-1 RNA, copies/mL,d,e n (%)
<50 120 (92.3) 12 (92.3) 263 (95.3) 395 (94.3)
≥50 10 (7.7) 1 (7.7) 13 (4.7) 24 (5.7)
Baseline CD4+ T-cell counts, cells/mm,d
n 129 13 276 418
Mean 571.9 595.0 559.2 564.2
SD 202.8 330.1 212.8 213.7
Baseline CD4+ T-cell counts, cells/mm,d n (%)
>50 to 200 2 (1.5) 0 (0.0) 6 (2.2) 8 (1.9)
>200 to 350 13 (10.0) 2 (15.4) 38 (13.8) 53 (12.6)
>350 to <400 11 (8.5) 0 (0.0) 19 (6.9) 30 (7.2)
≥400 103 (79.2) 11 (84.6) 213 (77.2) 327 (78.0)
Missing 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.2)
History of AIDS-defining illness, n (%)
No 105 (80.8) 8 (61.5) 200 (72.5) 313 (74.7)
Yes 25 (19.2) 5 (38.5) 76 (27.5) 106 (25.3)
Note: IR=immediate-release; NVP=nevirapine; XR=extended-release.
a Patients randomized to NVP IR and elected to change to NVP XR after week 48.
b Patients randomized to NVP IR and who chose to remain on NVP IR after week 48.
c Patients randomized to NVP XR who elected to remain on NVP XR after week 48.
d Baseline values are calculated as the average of the last 2 measurements prior to the start of randomized treatment.
eHIV-1 RNA viral load is based on TaqMan assay results.
Table 1: Baseline characteristics: post week 48.
Goto home»